Sugemalimab is a recombinant, fully human IgG4 lambda monoclonal antibody targeting programmed death-ligand 1 (PD-L1/CD274). It was developed as CS1001/WBP-315 and is produced in CHO cells. The FDA substance database classifies it as a protein/IgG4 monoclonal antibody, while the EMA assessment describes approximately 145.8 kDa theoretical molecular weight, with 448 amino acids in each heavy chain and 213 amino acids in each light chain.
Sugemalimab is identified by CAS 2256084-03-2 and FDA UNII 90IQR2I6TR. It is a full-length human monoclonal antibody of the IgG4 subclass and contains a lambda light chain. The antibody contains 16 disulfide bonds, including 12 intrachain and 4 interchain disulfide bonds.
The FDA substance record estimates an average molecular weight of approximately 143,000 Da, whereas the EMA assessment gives a theoretical molecular weight of approximately 145.8 kDa including glycosylation and C-terminal lysine cleavage. These values should not be treated as contradictory fixed small-molecule molecular weights because monoclonal antibodies are heterogeneous glycoproteins.
Sugemalimab is a biologic API manufactured through recombinant mammalian-cell technology. The commercial manufacturing process described by EMA uses a CHO-K1 cell line, followed by cell culture, harvest, primary capture, chromatography, viral inactivation, filtration and final freezing of the active substance.
As an IgG4 antibody, sugemalimab is structurally different from conventional synthetic APIs. Its quality is therefore assessed through a combination of identity, purity, molecular-size distribution, charge heterogeneity, glycosylation, aggregation, potency and microbiological/viral safety controls rather than conventional melting-point or small-molecule HPLC assay specifications.
Sugemalimab binds specifically to PD-L1, blocking its interaction with PD-1 and thereby supporting T-cell-mediated antitumour immune responses.
The European Union authorised Cejemly, containing sugemalimab, on 24 July 2024. It is authorised in combination with platinum-based chemotherapy for first-line treatment of adults with metastatic NSCLC without sensitising EGFR mutations or ALK, ROS1 or RET genomic tumour aberrations. It is also authorised as monotherapy for certain adults with unresectable stage III NSCLC whose tumours express PD-L1 on at least 1% of tumour cells and whose disease has not progressed following platinum-based chemoradiotherapy.
For Sugemalimab API, appropriate quality-control testing includes:
The EMA assessment confirms extensive characterization of the active substance and control of the recombinant manufacturing process.
Manufacturing Sugemalimab requires a controlled biologics manufacturing platform capable of recombinant antibody expression, purification and viral-safety control.
The EMA-described process uses CHO-K1 cells and multiple downstream purification operations, including chromatography, viral inactivation and filtration. The active substance is subsequently frozen for storage.
Because monoclonal antibodies exhibit molecular heterogeneity, API quality should be demonstrated using orthogonal analytical methods covering identity, purity, aggregation, charge variants, glycosylation and biological activity.
Sugemalimab active substance should be stored in validated pharmaceutical containers under controlled temperature conditions established by stability studies.
The finished Cejemly product is supplied as a 30 mg/mL concentrate, with 600 mg in a 20 mL vial. The finished medicinal product requires refrigerated storage at 2–8°C and protection from light.
Finished-product storage conditions should not automatically be transferred to the bulk API specification; API storage should follow its validated stability and container-closure program.
Sugemalimab API documentation may include:
Sugemalimab is a specialized recombinant monoclonal antibody API requiring sophisticated biologics manufacturing and analytical characterization. Its IgG4 structure, PD-L1 specificity, CHO-cell production and complex molecular attributes make orthogonal analytical control essential.
A suitable Sugemalimab API manufacturing program should therefore emphasize controlled recombinant production, validated purification, viral-safety controls, aggregation control, charge and glycan characterization, potency testing and comprehensive regulatory documentation.
| Parameter | Specification |
|---|---|
| Appearance | white to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |